SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

GT Biopharma Reports Third Quarter 2026 Financial Results

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with an update anticipated in Q4 2026Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 remains ongoing, with an update anticipated in Q4 2026FDA clearance of a new IND for GTB-5550 in multip…

GTBP

Related stories